Pharmaceutical firms advance late-stage therapies for Lp(a) cardiovascular risk

Drugmakers are nearing market entry for treatments targeting Lipoprotein(a), a genetic cardiovascular risk factor currently lacking approved pharmacological interventions. The development represents a significant shift in preventative cardiology, though clinical efficacy and regulatory approval timelines remain the primary variables for market impact.